Among adults with chronic spontaneous urticaria inadequately controlled by H1 antihistamine treatment, remibrutinib improved ...

If you're being treated for hives, your physician will want to hear what you think about your treatment. Is it working? Are your symptoms improving, staying the same, or getting worse? You may be ...

A panel of experts discuss the clinical trials of dupilumab, the resultant data, and the response of the FDA when approval was requested. Dupilumab has been evaluated in phase 3 clinical trials in ...

Washington, DC, Oct. 01, 2025 (GLOBE NEWSWIRE) -- On this Urticaria Day (UDAY), the Asthma and Allergy Foundation of America (AAFA), We CU, and The Mast Cell Disease Society (TMS) aim to raise ...

The FDA has approved Quzyttir for the treatment of acute urticaria in adults and children 6 months of age and older. The Food and Drug Administration (FDA) has approved Quzyttir (cetirizine ...

The approval marks the first for a targeted treatment in chronic spontaneous urticaria in Europe in over a decade.

Approval based on Phase 3 trials showing Dupixent significantly reduced itch and hives at 24 weeks compared to placebo In the EU, there are approximately 270,000 adults and adolescents aged 12 years ...

"Medical Journeys" is a set of clinical resources reviewed by physicians, meant for the medical team as well as the patients they serve. Each episode of this journey through a disease state contains ...

BeOne Medicines ((ONC)) announced an update on their ongoing clinical study. Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights ...

Norovirus doesn’t usually cause a rash, though some people develop hives. A rash that accompanies stomach symptoms may suggest a different stomach virus or inflammatory bowel disease. Norovirus is a ...